Osteoarthritis study
This article was originally published in The Tan Sheet
Executive Summary
Spanish firm BioIberica will supply chondroitin sulfate for the NIH-funded study on osteoarthritis, an NIH steering committee decides Sept. 28. Pfanstiehl Labs is providing the glucosamine. The trial, co-sponsored by NCCAM and NIAMS, was slated to start several months ago but was stalled due to difficulty in choosing supplement suppliers (1"The Tan Sheet" Sept. 4, p. 4). Enrollment is expected to begin in late October
You may also be interested in...
Suppliers See Ingredient Branding As Key To Greater Market Presence
Supply firms are focusing on branding their ingredients as they pursue category leadership within the dietary supplement industry
Glucosamine/Chondroitin Supplier Selection Delays NIH Study
Difficulty in choosing a U.S. company to supply glucosamine and chondroitin sulfate has delayed the start of the NIH-funded study on osteoarthritis.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC